RNC Capital Management LLC Buys 5,485 Shares of Pfizer Inc. (NYSE:PFE)

RNC Capital Management LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 8.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 67,955 shares of the biopharmaceutical company’s stock after buying an additional 5,485 shares during the period. RNC Capital Management LLC’s holdings in Pfizer were worth $2,501,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in PFE. NuWave Investment Management LLC lifted its position in shares of Pfizer by 439.7% in the third quarter. NuWave Investment Management LLC now owns 1,468 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 1,196 shares during the last quarter. Dimension Capital Management LLC acquired a new stake in shares of Pfizer in the third quarter valued at approximately $58,000. Sumitomo Mitsui Financial Group Inc. acquired a new stake in shares of Pfizer in the third quarter valued at approximately $59,000. Demars Financial Group LLC bought a new position in shares of Pfizer during the second quarter worth approximately $75,000. Finally, RMR Wealth Builders bought a new position in shares of Pfizer during the second quarter worth approximately $91,000. 69.08% of the stock is owned by institutional investors.

In other news, major shareholder Pfizer Inc acquired 1,200,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 27th. The stock was bought at an average price of $10.00 per share, with a total value of $12,000,000.00. Following the acquisition, the insider now owns 27,349,211 shares in the company, valued at approximately $273,492,110. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.08% of the stock is currently owned by company insiders.

PFE has been the topic of a number of recent research reports. BidaskClub lowered Pfizer from a “sell” rating to a “strong sell” rating in a research note on Thursday, December 31st. TheStreet upgraded Pfizer from a “c+” rating to a “b-” rating in a research note on Wednesday, November 25th. Berenberg Bank initiated coverage on Pfizer in a research note on Tuesday, September 29th. They set a “hold” rating and a $38.00 price objective on the stock. Sanford C. Bernstein initiated coverage on Pfizer in a research note on Tuesday, November 10th. They set a “market perform” rating and a $42.00 price objective on the stock. Finally, Mizuho raised their price objective on Pfizer from $43.00 to $44.00 and gave the stock a “buy” rating in a research note on Tuesday, November 10th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $39.87.

Shares of PFE opened at $36.86 on Thursday. The company has a market capitalization of $204.88 billion, a PE ratio of 14.63, a PEG ratio of 3.10 and a beta of 0.66. Pfizer Inc. has a 12 month low of $27.88 and a 12 month high of $43.08. The stock’s 50-day moving average price is $38.25 and its two-hundred day moving average price is $37.19. The company has a current ratio of 1.42, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 27th. The biopharmaceutical company reported $0.72 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.71 by $0.01. The firm had revenue of $12.13 billion for the quarter, compared to the consensus estimate of $12.30 billion. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The business’s quarterly revenue was down 4.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.75 EPS. Equities research analysts predict that Pfizer Inc. will post 2.84 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 5th. Investors of record on Friday, January 29th will be issued a $0.39 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.38. This represents a $1.56 dividend on an annualized basis and a dividend yield of 4.23%. The ex-dividend date of this dividend is Thursday, January 28th. Pfizer’s dividend payout ratio (DPR) is currently 51.53%.

About Pfizer

Pfizer Inc develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands.

See Also: How prevalent are 12b-1 fees?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.